|
- B-cell activating factor - Wikipedia
BAFF is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family This cytokine is a ligand for receptors TNFRSF13B TACI, TNFRSF17 BCMA, and TNFRSF13C BAFF-R This cytokine is mainly expressed by myeloid cells, dendritic cells, and stromal cells, and acts as a potent B cell activator
- The BAFF Protein’s Role in Immune Health and Disease
BAFF is an important cytokine that helps regulate both innate and adaptive immune responses It is particularly important for the development, survival, and maturation of B cells, which are specialized white blood cells responsible for producing antibodies that fight off infections
- Exploratory analysis of B-cell activating factor (BAFF) and a . . .
BAFF levels increased during the ictal phase (p = 0 011) and declined in the post-ictal phase, whereas APRIL remained consistently downregulated relative to controls The divergent patterns of BAFF and APRIL reveal a novel B-cell–related immune signature that may contribute to migraine pathogenesis
- An Essential Role for BAFF in the Normal Development of B . . . - Science
in mice established that BAFF can cause a systemic lupus erythematosis (SLE)-like syndrome (13,14) Since circulating levels of BAFF are elevated in some lupus patients (15,16), there has been great interest further understanding the possible roles of this ligand
- The BAFF APRIL system: Emerging functions beyond B cell biology and . . .
In this review, we provide the latest views on additional roles of the BAFF system in health and diseases, as well as an update on BAFF and autoimmunity, with particular focus on current clinical trials
- BAFF receptor - Wikipedia
B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular phenylalanine -rich domain
- BAFF is a marker of hypogammaglobulinemia, neuroaxonal . . . - Springer
Background and objectives Serum biomarker testing for multiple sclerosis has been increasing in popularity in research and clinical practice Little evidence is available on influences of disease modifying therapy on serum biomarker levels Interpretation of clinically available serum biomarkers in the context of each individual patient poses a greater challenge in this context This study
|
|
|